Risto
Lammintausta , M.

Approximately 6,000 children suffer from Severe
Primary IGFD and could become eligible for Increlex(TM) therapy if approved by
the FDA.

About Tercica
Tercica, Inc.

endocrineweb parathyroid

Zerbe, M., formerly CEO at Hormos, will join the senior
management team at QuatRx. Combined
with our strong financial position and our existing product pipeline to treat
metabolic and cardiovascular diseases, this transaction significantly enhances
QuatRx's efforts to build a world-class portfolio of development-stage
therapeutics with significant market potential," Dr.D.

About QuatRx
QuatRx Pharmaceuticals Company, a biopharmaceutical company, focuses on
research and development of therapeutic compounds primarily for the treatment
of major endocrine, metabolic and cardiovascular diseases, especially
dyslipidemia and endocrine diseases of aging. in room 151. A sub-set of these children, whose
height and serum IGF-1 levels are more than three standard deviations below
normal , may be diagnosed with Severe Primary IGFD.

glands pancreas

, Ph. Fispemifene is a therapeutic agent for the treatment of androgen
deficiency and associated conditions in aging men. Becocalcidiol,
which has just completed Phase II clinical studies, is a vitamin D analogue
for the topical treatment of psoriasis without the liability of hypercalcemia
associated with current therapies. (Nasdaq: TRCA) announced today that two poster presentations related to
the frequency of primary insulin-like growth factor -1 (IGF-1) deficiency
(Primary IGFD) and safety of recombinant human IGF-1 (rhIGF-1) therapy in
children with short stature will be presented at the Pediatric Academic
Societies (PAS) 2005 Annual Meeting .

endocrineweb hyperlipidemia

QRX-431, which is undergoing
preclinical studies, works as an agonist on a specific thyroid receptor ,
helping to increase metabolism without creating negative cardiac effects while
still promoting the hepatic functions that help lower lipid levels. The presentation will take place as part of PAS on Sunday,
May 15 at 8:00 a.
Primary IGFD can be caused by abnormalities of either the growth hormone
receptor or growth hormone signaling pathway.

untreated hamartoma

Both therapies work to deliver the
benefit of hormone treatment with a more targeted approach designed to avoid
the side effects often associated with broad hormone therapy. The research activities of the company are based on
its expertise in tissue-specific steroid hormone effects at the molecular and
cellular level. Pinchas Cohen, director of pediatric endocrinology
at Mattel Children's Hospital at UCLA
Data presented highlight the frequency of IGF-1 deficiency (IGFD) among
patients currently classified as idiopathic short stature (ISS) or short
stature due to unknown causes, in an observational study of U. The presentation will take place as part of PAS
on Sunday, May 15 at 8:00 a.D.

About IGF-1 and Primary IGFD
IGF-1 is the principal hormone necessary for statural growth.
Primary IGFD afflicts an estimated 30,000 children evaluated for short
stature in the United States.

bmc parathyroid

Ospemifene , a selective estrogen receptor modulator
(SERM) for the treatment of conditions and symptoms associated with declining
estrogen levels in postmenopausal women, is positioned to enter Phase 3
studies .

pancreas endocrineweb

Robert L. Lammintausta. QRX-
401, currently in advanced Phase 1 trials, is positioned as an alternative
treatment option for use alone or in combination with statins, fibrates and
other current lipid treatment programs. children
referred for growth failure., acquired exclusive rights to develop, commercialize and
manufacture Increlex from Genentech, Inc.

Diseases that affect the secretion by endocrine glands.

hamartoma polyglandular

Under the terms
of the transaction, Hormos will become a wholly-owned subsidiary of QuatRx.

hamartoma dwarfism

"With the added resources of Hormos in the endocrine area, QuatRx is
taking a significant step forward in our strategy to develop new therapies to
treat major health problems affecting millions of people worldwide. QuatRx's lead dyslipidemia products, QRX-401 and QRX-431,
have novel dual mechanisms of action designed to reduce the levels of LDL and
Lp(a), both independent markers for premature coronary heart disease.
With this transaction, a representative of the Hormos investor group will
join the QuatRx Board of Directors. With significant financial backing from top-tier venture
capital firms and strong development capabilities, QuatRx continues to advance
and expand its portfolio of development-stage compounds., Tercica,
Inc. If untreated, Primary IGFD may
lead , in children and adults, to a range of other metabolic disorders
including lipid abnormalities, decreased bone density, obesity and insulin
resistance.

polyglandular endocrinology

Focus on Primary IGF-1 Deficiency as Frequent Cause of Short Stature and
rhIGF-1 Safety

SOUTH SAN FRANCISCO , Calif.

polyglandular pituitary

D. By combining
this focus with the development expertise and resources available at QuatRx ,
the merged organization is exceptionally well-positioned to advance a new
generation of estrogen and androgen therapies that will offer significant
advantages over other agents," said Dr. Primary IGFD, a cause
of short stature that is 1.

glands endocrinologists

ANN ARBOR, Mich. QuatRx has its headquarters in
Ann Arbor, Michigan, with a significant presence in Europe through Hormos
Medical Corp (a wholly -owned subsidiary of QuatRx Pharmaceuticals Company),
located in Turku, Finland.C. in room 151. Tercica currently is conducting a
broad-scale Phase IIIb clinical study to evaluate the safety and efficacy of
Increlex in children with Primary IGFD.

endo dwarfism

,
chief medical officer at QuatRx.S.

syndromes aace

"The identification and development of targeted therapies with advanced
tissue-specific profiles has been the core competence of Hormos.
"The QuatRx management team has extensive experience in all phases of
product development for both metabolic and endocrine products.
"These presentations underscore the important rationale for diagnosis and
treatment of Primary IGFD in a significant number of short children with a
previously unrecognized disorder," said George Bright, M.5 times more common than growth hormone deficiency,
may be diagnosed in children who have normal or elevated secretion of
endogenous growth hormone and whose height and serum IGF-1 levels are more
than two standard deviations below normal. Because Tercica 's forward-
looking statements are subject to risks and uncertainties, there are important
factors that could cause actual results to differ materially from those in the
forward-looking statements .

endocrine ohsu

Zerbe said.
With the completion of this transaction, QuatRx's product pipeline will
include two candidates positioned to enter Phase 3 clinical trials, two
development programs positioned to enter Phase 2 trials in the next year, a
candidate positioned to enter Phase 1 studies, and an expanded portfolio of
earlier stage programs. These factors include without limitation: (1)
those risks and uncertainties disclosed from time to time in reports filed by
Tercica with the SEC, most recently Tercica's Form 10-K filed on March 24,
2005; and (2) Tercica's estimates might not accurately reflect the number of
children afflicted with Primary IGFD and Severe Primary IGFD.

pathophysiology bmc

, president and CEO of
QuatRx, will be president and CEO of the combined company. QuatRx plans to initiate
Phase 2 studies for fispemifene in 2005.
QuatRx is also developing a new treatment for psoriasis., Vice President
and Medical Director of Endocrinology at Tercica. IGF-1 is
released in response to stimulation by growth hormone.

Safe Harbor Statement
Except for the historical statements contained herein, this press release
contains forward-looking statements, including without limitation the
following: (A) that Primary IGFD afflicts an estimated 30,000 children
evaluated for short stature in the United States; and (B) that approximately
6,000 children suffer from Severe Primary IGFD and could become eligible for
Increlex(TM) therapy if approved by the FDA.

polyglandular parathyroid

D. is a biopharmaceutical company focused on the development
and commercialization of products to improve endocrine health.com.

glands pancreas

These patients will have less severe
disease than the patients in Tercica's Phase III studies included in the
company's NDA.

ohsu secretion

Merger expands QuatRx's development portfolio targeting major
metabolic/endocrine diseases associated with aging.
The merger with Hormos will immediately add two clinical-stage compounds
to the QuatRx pipeline.m.

Absence of Hypoglycemia in Response to Varying Doses of Recombinant Human
Insulin-Like Growth Factor-I (rhIGF-I) in Children and Adolescents with Low
Serum Concentrations of IGF-I, Presented by Dr. Arlan Rosenbloom of the
University of Florida
These preliminary findings will examine the correlation between children
with low concentrations of IGF-I and insulin-like growth factor-binding
protein 3 (IGFBP3) and their risk for hypoglycemia in response to rhIGF-I
administration.m. These
statements are based on information as of May 13, 2005, and the Company
assumes no obligation to update any forward-looking statement.

pathophysiology untreated

Tercica Announces Two Presentations at Pediatric Academic Societies 2005 Annual Meeting

The meeting is being held May 14-17 in
Washington, D.

polyglandular metabolic

Presentations include:

IGF-1 Deficiency with Short Stature, a New Diagnostic Sub-set Separate
from ISS? Presented by Dr.

About Increlex(TM)
Tercica, Inc.

adrenal pituitary

, and TURKU, Finland, QuatRx
Pharmaceuticals Company, a privately-held biopharmaceutical company developing
new therapies to treat cardiovascular , metabolic and endocrine diseases, has
announced a merger with Hormos Medical Corporation, a biopharmaceutical
company based in Turku, Finland, focused on research and development of
products to treat endocrine disorders associated with aging.
The combined entity, which will be known as QuatRx Pharmaceuticals , will
bring together the complementary resources of the two companies and will be
headquartered at the current QuatRx facility in Ann Arbor, MI, and have
offices in Turku, Finland.D.tercica.

syndromes endocrinology

QuatRx is also continuing to develop its pipeline of product opportunities
in dyslipidemia. As a result,
there are significant synergies in combining this experience with the strong
focus on endocrine product development at Hormos," said Randy Whitcomb, M. The company's
first product candidate , Increlex(TM) (mecasermin (rDNA origin) injection), or
recombinant human insulin-like growth factor -1 (rhIGF-1), is being developed
for the treatment of short stature and associated metabolic disorders .

adrenal endocrineweb

QuatRx Pharmaceuticals Announces Merger With Hormos Medical

QuatRx's robust pipeline includes four compounds
in clinical development.

untreated hyperlipidemia

Major investors from Hormos will also
make an additional investment in QuatRx as an extension of a recent round of
venture financing in QuatRx. For
further information on Tercica, please visit http://www.

amyloidosis hyperlipidemia